Bibliography
- Bove R, Chitnis T. Sexual disparities in the incidence and course of MS. Clin Immunol 2013;149:201-10
- Harbo HF, Gold R, Tintoré M. Sex and gender issues in multiple sclerosis. Ther Adv Neurol Disord 2013;6(4):237-48
- Alwan S, Yee IM, Dybalski M, et al. Reproductive decision making after the diagnosis of multiple sclerosis (MS). Mult Scler 2012;19(3):351-8
- Finkelsztejn A, Brooks J, Paschoal F Jr, et al. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of literature. BJOG 2011;118:790-7
- Confavreux C, Hutchinson M, Hours M, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998;339:285-91
- Sicotte NL, Liva SM, Klutch R, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 2002;52:421-8
- Coyle PK. Multiple sclerosis in pregnancy. Continuum (N Y) 2014;20(1):42-59
- Hughes SE, Spelman T, Gray OM, et al. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler 2014;20(6):739-46
- Miller DH, Fazekas F, Montalban X, et al. Pregnancy, sex and hormonal factors in multiple sclerosis. Mult Scler 2014;20(5):527-36
- Cree BAC. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler 2013;19(7):835-43
- Hellwig K, Schimrigk S, Chan A, et al. A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. J Neurol Sci 2011;307(1):164-5
- Lu E, Wang BW, Guimond C, et al. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology 2012;79:1130-5
- Coyle PK, Sinclair SM, Scheuerle AE, et al. Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events. BMJ Open 2014;4:e004536
- Hellwig K, Haghikia A, Rockhoff M, et al. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord 2012;5(5):247-53
- Fragoso YD, Adoni T, Alves-Leon SV, et al. Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review. CNS Drugs 2013;27(11):955-61
- Lu E, Zhu F, Zhao Y, et al. Birth outcomes of pregnancies fathered by men with multiple sclerosis. Mult Scler 2014;20(9):1260-4
- Pecori C, Giannini M, Portaccio E, et al. Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurol 2014;14:114
- Ghezzi A, Annovazzi P, Portaccio E, et al. Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. Expert Rev Clin Immunol 2013;9(7):683-91
- Haghikia A, Langer-Gould A, Rellensmann G, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol 2014;71(7):891-5
- Dung AA, Panda AK. Interferon β-1a therapy for multiple sclerosis during pregnancy: an unresolved issue. BMJ Case Rep 2014. doi: 10.1136/bcr-2013-201273
- Salminen HJ, Leggett H, Boggild M. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J Neurol 2010;257(12):2020-3
- Hutchinson M. One can prevent post-partum MS relapses by exclusive breast feeding: commentary. Mult Scler 2013;19(12):1569-70
- Langer-Gould A, Hellwig K. One can prevent post-partum MS relapses by exclusive breast feeding: yes. Mult Scler 2013;19(12):1567-8
- Vukusic S, Confavreux C. One can prevent post-partum MS relapses by exclusive breast feeding: no. Mult Scler 2013;19(12):1565-6